Table 1.
Baseline Characteristics
| Group 1 Diabetic Patients | Group 2 Control group | p | |
|---|---|---|---|
| Number of patients, n | 105 | 105 | ns |
| Gender (male/female),n | 92/13 | 92/13 | ns |
| Age (years), mean ± SD | 65.4 ± 9.4 | 63.3 ± 5.5 | ns |
| BMI (Kg/m2), mean ± SD | 28.3 ± 3.4 | 28. ± 5 4 | ns |
| Serum creatinine (mg/dl), mean ± SD | 1.12 ± 0.3 | 1.04 ± 0.2 | ns |
| CLINICAL HISTORY | |||
| Angina, n (%) | 54 (51%) | 62 (59%) | ns |
| Inconclusive stress test, n(%) | 56 (53%) | 62 (58%) | ns |
| Valvular disease, n (%) | 0 (0%) | 2 (2%) | ns |
| Arrhytmia, n (%) | 0 (0%) | 2 (2%) | ns |
| DCM, n (%) | 12 (8%) | 10 (9.5%) | ns |
| CARDIOVASCULAR RISK FACTORS | |||
| Diabetes mellitus, n (%) | 105 (100%) | 0 (0%) | 0.01 |
| Insulin dependent, n (%) | 12 (11.5%) | - | - |
| Glycosylated haemoglobin (%) | 7.1 ± 2.4% | - | - |
| Hypertension, n (%) | 74 (70%) | 63 (60%) | ns |
| Hypercholesterolemia, n (%) | 59 (56%) | 45 (43%) | ns |
| Current smoking, n (%) | 31 (30%) | 29 (28%) | ns |
| Family history of CAD, n (%) | 21 (20%) | 27 (26%) | ns |
| PRE-TEST LIKELIHOOD OF CAD | 51% | 52% | ns |
| β-BLOCKER | |||
| Number of patients, n (%) | 66 (63%) | 63 (60%) | ns |
| Dose (mg), mean ± SD | 11.2 ± 5.3 | 11.4 ± 2.5 | ns |
| HEART RATE (bpm), mean ± SD | 61.2 ± 9.3 | 58 ± 4.6 | ns |
| AGATSTON SCORE | |||
| mean ± SD | 479 ± 492 | 356 ± 367 | 0.01 |
| median (range) | 346 (0-1740) | 240 (0-1650) | 0.01 |
| CAD extension | |||
| 0-vessel, n (%) | 10 (11%) | 18 (13%) | ns |
| 1-vessel, n (%) | 28 (27%) | 20 (19%) | ns |
| 2-vessel, n (%) | 33 (30%) | 34 (34%) | ns |
| 3-vessel, n (%) | 34 (32%) | 33 (34%) | ns |
BMI = Body mass Index; CAD = Coronary artery disease; DCM = Dilated cardiomiopathy;
DS = standard deviation.